Dianthus Therapeutics
DNTH
98 hedge funds and large institutions have $685M invested in Dianthus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 12 closing their positions.
67% more capital inflows, than outflows
Capital inflows: $143M | Capital outflows: $85.6M
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
8.06% more ownership
Funds ownership: 109.34% → 117.4% (+8.1%)
3% more funds holding
Funds holding: 95 → 98 (+3)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
53% less call options, than puts
Call options by funds: $813K | Put options by funds: $1.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$52M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.5M |
| 3 |
RA Capital Management
Boston,
Massachusetts
|
+$22M |
| 4 |
Vestal Point Capital
New York
|
+$13.8M |
| 5 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$25.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$18.3M |
| 3 |
RTW Investments
New York
|
-$14.5M |
| 4 |
Janus Henderson Group
London,
|
-$8.86M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.65M |
DNTH Hedge Fund Activity: Q1 2025 in Review
98 of the 7,478 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2025, worth a combined $685M — down 10% from $766M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new DNTH positions and 12 closed out — a net gain of 3 holders — while 29 added to existing stakes and 32 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $52M. The largest seller was Avidity Partners Management, cutting an estimated $25.4M.
- 98 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2025, up from 95 in Q4 2024.
- Funds reported $685M of Dianthus Therapeutics stock for Q1 2025, down 10% quarter-over-quarter.
- 15 funds opened new Dianthus Therapeutics positions in Q1 2025 and 12 closed out, a net change of +3 holders.
- The largest Dianthus Therapeutics buyer in Q1 2025 was Deep Track Capital, an estimated $52M added.
- The largest Dianthus Therapeutics seller in Q1 2025 was Avidity Partners Management, an estimated $25.4M sold.
Based on aggregated 13F filings for Q1 2025.